Bring the potential of ROZLYTREK® to life
ROZLYTREK demonstrates clinically meaningful and durable responses in NTRK fusion+ tumours and ROS1+ NSCLC, irrespective of baseline CNS metastases1
ROZLYTREK demonstrates clinically meaningful and durable responses in NTRK fusion+ solid tumours and ROS1+ NSCLC, irrespective of baseline CNS metastases1
ROZLYTREK is a tyrosine kinase inhibitor with a well-tolerated and consistent safety profile in both adult and paediatric patients1,2
Therapeutic indications1
ROZLYTREK as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older, with solid tumours, expressing a NTRK gene fusion:
• who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
• who have not received a prior NTRK inhibitor,
• who have no satisfactory treatment options.
ROZLYTREK as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced NSCLC not previously treated with ROS1 inhibitors.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for details on how to report adverse reactions.
Footnotes
CNS, central nervous system; NSCLC, non-small cell lung cancer; NTRK, neurotrophic tyrosine receptor kinase; ROS1, c-ros oncogene ; SmPC, summary of product characteristics; TRK, tyrosine kinase.
References
- ROZLYTREK Summary of Product Characteristics, 2020.
- Patel M, et al. Ann Oncol 2020;31(Suppl 3):232–233.